---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-24-000017"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:15:33.813586+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbCellera FY2023 revenue $38M (down 92% YoY), net loss $0.51/share

## Summary
- Revenue fell to $38.0M from $485.4M in FY2022; research fees were $35.6M.
- Net loss of $146.4M ($0.51 basic & diluted EPS) vs net income of $158.5M in 2022.
- R&D expenses surged to $175.7M (up 63% YoY) on program and platform investments.
- Cumulative partner-initiated program starts reached 87; 13 molecules in clinic.
- Advanced two internal programs (ABCL635, ABCL575) into IND-enabling studies.

## SEC filing metadata
- accession: 0001703057-24-000017
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305724000017/0001703057-24-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305724000017/abcl-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-24-000017
- JSON: https://secwatch.observer/filing/0001703057-24-000017.json
- Plain text: https://secwatch.observer/filing/0001703057-24-000017.txt

## Key facts
- Earnings Releases
  AbCellera Biologics Inc. reported full year 2023 results: revenue $38.0 million, net income $146.4 million, or $(0.51) per share on a basic and diluted basis, EPS $(0.51) per share on a basic and diluted basis.
  - Period: full year 2023
  - Revenue: $38.0 million
  - Net income: $146.4 million, or $(0.51) per share on a basic and diluted basis
  - EPS: $(0.51) per share on a basic and diluted basis
  - Result: reported results
  source text: the press release is furnished herewith as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- NEWS RELEASE AbCellera Reports Full Year 2023 Business Results 2/20/2024 ● Total revenue of $38 million, compared to $485 million in FY 2022 ● Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year ● Net loss of $0.51 per share on a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305724000017/0001703057-24-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.